The study confirmed that HER2 status is a predictive biomarker of responsivity to T-DXd; however, an important activity of T-Dxd was also confirmed in patients whose cancer expressed lower levels of HER2 or did not express HER2. The gene discussed is ERBB2; the disease is cancer.